• Everolimus (RAD001): Readouts That Matter

  2026-08-20

  Everolimus (RAD001) is an orally bioavailable mTOR inhibitor whose pathway activity should be separated from cytostasis and cell death. This assay-centered guide shows how to design more informative cancer experiments by integrating mechanistic, proliferation, and apoptosis readouts.

• IRG1-Itaconate Control of TBK1 and Type I IFN

  2026-08-20

  A 2025 Cell Reports study identifies the IRG1–itaconic acid axis as a metabolic feedback mechanism that restrains excessive TBK1-driven type I interferon production. The work connects itaconic acid–dependent alkylation of TBK1 at Cys605 with impaired dimerization and introduces ITA-5 and ITA-9 as candidate inhibitors for IFN-I-mediated hyperinflammation.

• Rapamycin (Sirolimus) for mTOR Assays

  2026-08-19

  Rapamycin (Sirolimus) provides a precise chemical perturbation strategy for mTOR-driven studies spanning cancer, autophagy, immunology, and mitochondrial disease models. This practical guide connects dose–time design with EBV-associated gastric cancer biology, pathway validation, and troubleshooting for reproducible cell assays.

• PP 2 (AG 1879): From Src Biology to Translation

  2026-08-19

  PP 2 (AG 1879) is more than a Src-family kinase reagent: it is a context-dependent probe for separating target engagement from pathway causality. This article connects its cancer and immune applications with vascular evidence showing that Src inhibition can reduce contraction without mediating NADPH oxidase-derived ROS effects, providing a practical framework for translational study design.

• TPPU: Soluble Epoxide Hydrolase Inhibitor Workflows

  2026-08-18

  TPPU is a nanomolar soluble epoxide hydrolase inhibitor for connecting fatty acid epoxide signaling with inflammatory pain, osteoclastogenesis, and Nrf2 biology. This workflow-focused guide shows how to formulate it, confirm EET/DHET target engagement, and troubleshoot cell, lipidomics, and cross-species experiments.

• BPN-19186: Osteoclastogenesis Assay Workflows

  2026-08-18

  BPN-19186 provides a practical small-molecule entry point for testing enzyme inhibition studies, redox signaling, and osteoclast differentiation without relying exclusively on genetic perturbation. This workflow emphasizes exposure control, orthogonal Nrf2-related readouts, metabolite analysis, and troubleshooting for reproducible biochemical research.

• KU-60019: ATM Kinase Inhibitor Workflow

  2026-08-17

  KU-60019 supports controlled studies of ATM-dependent DNA damage signaling, glioma radiosensitization, and migration or invasion phenotypes. This workflow connects selective pathway inhibition with practical assay controls, formulation guidance, and mechanistic experiments inspired by lncRNA-regulated ATM biology.

• Losartan for AT1R and Diabetic Kidney Research

  2026-08-17

  Losartan combines selective AT1 receptor antagonism with a practical workflow for connecting angiotensin II signaling to vascular and podocyte phenotypes. This guide translates recent diabetic nephropathy findings into assay-ready dosing, internalization measurements, matrix readouts, and troubleshooting strategies.

• Phosbind Acrylamide for Phosphorylation Analysis

  2026-08-16

  Phosbind Acrylamide enables antibody-independent separation of phosphorylated and non-phosphorylated proteins in a familiar SDS-PAGE workflow. This article shows how to apply it to heat-stress transcription studies, kinase assays, control design, and troubleshooting when phosphorylation-dependent mobility shifts are subtle.

• Recombinant Human FGF-19 Assay Guide

  2026-08-15

  A scenario-based guide to using Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized), SKU P1050, in proliferation, viability, binding, and metabolic regulation research. It connects product specifications with practical controls, reconstitution, storage, and interpretation strategies for reproducible cell-based assays.

• Sumatriptan: Receptor-to-Metabolite Assay Logic

  2026-08-14

  Sumatriptan Succinate is more than a standard 5-HT1 receptor agonist: its metabolic fate can materially shape assay interpretation. This guide connects receptor pharmacology, CGRP biology, and CYP–MAO metabolism to improve experimental design and translational judgment.

• Puerarin Activates NO Signaling in Dental Follicle Cells

  2026-08-14

  The reference study shows that puerarin enhances osteogenic differentiation in rat dental follicle cells and associates this response with activation of the NO–cGMP–SGC/PKG-1 signaling axis. Pharmacological NOS inhibition weakened the response, supporting a mechanistic role for nitric oxide pathway modulation while leaving questions about NOS isoform specificity and in vivo relevance.

• Sumatriptan Succinate Workflow Guide

  2026-08-13

  Build reproducible migraine, neurovascular, inflammation, and metabolism assays with Sumatriptan Succinate, a selective 5-HT1 receptor agonist. This guide converts pediatric emergency-care evidence into practical bench workflows while emphasizing concentration control, receptor-aware interpretation, and troubleshooting.

• AG-126: ERK Assays for Striatal Signaling

  2026-08-13

  AG-126 provides a practical perturbation tool for testing whether ERK1/2 signaling contributes to neuronal hyperactivation, inflammatory responses, or cytokine output. This workflow connects the NLGN1–D2-MSN repetitive-behavior findings with carefully controlled in vitro ERK assays while clearly separating established evidence from proposed extensions.

• Selonsertib (GS-4997) Experimental Workflows

  2026-08-12

  Selonsertib (GS-4997) enables selective ASK1 pathway perturbation in oxidative-stress, inflammation, fibrosis, and metabolic disease models. This guide translates the Galectin-1–FIP200 autophagy findings into practical assay designs while separating established evidence from testable experimental extensions.

8352 records 4/557 page Previous Next 12345 下5页 Last page